A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Summary

The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.

Timeline

Start

2023-08-21

Primary completion

2024-10-09

Completion

2024-10-09

Outcome

Met primary endpoint

registry analysis (superiority test); 5 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -1.42 (95% CI -1.76 to -1.07); ANCOVA NCT05963022 ↗

registry analysis (superiority test); 10 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -0.98 (95% CI -1.34 to -0.63); ANCOVA NCT05963022 ↗

registry analysis (superiority test); 15 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -1.26 (95% CI -1.61 to -0.92); ANCOVA NCT05963022 ↗

Publications

• Yin Y, Ma J, Liu D, Duan W, Cheng Z, Jiang H, Zhang Y, Wu G, Zhuang H, Gu W, Mu Y. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Med. 2026 Jul 10;7(7):101183. doi: 10.1016/j.medj.2026.101183. Epub 2026 Jun 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirzepatide	Peptide	5 mg	Subcutaneous
Subject	Tirzepatide	Peptide	10 mg	Subcutaneous
Subject	Tirzepatide	Peptide	15 mg	Subcutaneous

Indications